Filspari
Filspari ingredients
| Active ingredient | Strength |
|---|---|
| Sparsentan | 400 mg/1, 200 mg/1 |
What Filspari is used for
The FDA lists the approved uses on the official label (below). In the EU, sparsentan is approved as Filspari for:
Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine ratio > 0.75 g/g, see section 5.1).
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Filspari
- Generic name
- Sparsentan
- Made by
- Travere Therapeutics, Inc.
- Forms
- Tablet, Film Coated
- Given
- Oral
- Drug class
- Angiotensin 2 Receptor Blocker, Endothelin Receptor Antagonist
- FDA approval
- New drug application (NDA) NDA216403
- On the US market since
- 2023
Official information
- Filspari prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Sparsentan)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Filspari?
Filspari (Sparsentan) is a specialist medicine made by Travere Therapeutics, Inc., approved by the US FDA.
What are the ingredients of Filspari?
Filspari contains Sparsentan (400 mg/1, 200 mg/1).
Is Filspari approved in Europe?
The same active substance is approved in the EU as Filspari.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA